The Frontier

Peter Attia states breast cancer is the fourth-leading cause of cancer death after lung, colorectal, and pancreatic cancer.

Attia cites CISNET models showing annual mammography for women 40-79 yields a 42% mortality reduction versus 30% for biennial screening, translating to 230 life-years gained per 1,000 women annually versus 165 biennially.

Attia notes observational data shows women screening annually had an 11% interval cancer rate versus 38% for biennial screeners, and annual screening led to 76% stage one diagnoses versus 56% for biennial.

Attia argues aggressive cancers comprise 7-10% of cases, eluding even perfect screening, while underscreening is the larger, solvable problem.

Attia states about 20% of women 50-74 are not up-to-date on mammograms, and at least 9% qualify for MRI under guidelines but only 0.4% get it.

Attia recommends a formal risk assessment by age 25 to determine if you are truly average risk or need earlier, more intensive screening.

Attia says BRCA mutations occur in about 1 in 400 people overall but are more prevalent in Ashkenazi Jewish ancestry, while triple-negative cancers account for 20% of cases in women under 40 versus 6-12% in older women.

Attia notes breast cancer risk is cumulative; only about 5% of diagnoses occur under age 40, and cumulative risk through age 40 is less than 1%.

Attia cites a study of 6 million mammograms showing cancer detection rates: 2.1 per 1,000 for women 35-39 with risk factors versus 0.59 per 1,000 for average-risk women, and 0.71 per 1,000 for average-risk women 40-44.

Attia says triple-negative cancers can double in size in under four months, making annual screening insufficient for some high-risk younger women.

Attia states about 50% of screening-age women have dense breast tissue, which both raises baseline risk and reduces mammogram sensitivity.

Attia explains DCIS, found via mammography, has a 25-60% chance of progressing to invasive cancer, justifying its detection.

Attia notes adding MRI to mammography for dense breasts halved interval cancer rates from 5 per 1,000 to 2.5 per 1,000.

Attia cites studies showing handheld ultrasound added to 2D mammography increased detection by 4.2 per 1,000, while adding it to DBT only boosted detection by 1.1 per 1,000.

Attia argues inflammatory breast cancer accounts for 1-5% of cases, often lacks a discrete lump, and requires diagnostic workup as it may not appear on screening mammograms.